Vaccine

An experimental personalized cancer vaccine for melanoma from Merck and Moderna has shown positive preliminary results in its first late-stage trial. The combination therapy significantly extended the time patients lived without recurrence.

An experimental personalized cancer vaccine from Merck and Moderna has shown positive preliminary results in a Phase 3 trial. The combination therapy significantly reduced the risk of melanoma recurrence.

The US Food and Drug Administration (FDA) has approved Moderna's Mfalusiva, the first seasonal flu vaccine based on mRNA technology. In a large-scale trial, the vaccine showed a 26.6% higher relative efficacy compared to a standard-dose flu vaccine.